| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
III |
in corso |
Melanoma avanzato |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
|
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (ENGOT-en23/GOG3095) |
III |
in corso |
Carcinoma endometriale |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial |
II |
in corso |
TUMORI GASTROENTEROPANCREATICI (GEP) |
- SC Oncologia Clinica Sperimentale dei Sarcomi e Tumori Rari |
|
Potenziale ruolo protettivo degli inibitori di SGLT-2 sulla cardiotossicità indotta da chemoterapia (PROTECT trial) |
II |
in corso |
Cancro della mammella |
- SC Cardiologia |
|
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) |
III |
in corso |
Cancro della cervice uterina localmente avanzato |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
